Original papers in peer-reviewed journals:

1. Pozo-Rosich P (CA), van Veelen N, Caronna E, Vaghi G, Torres-Ferrus M, van der Arend BWH, Goadsby PJ, Ashina M, Wang SJ, Diener HC, Tassorelli C, Terwindt GM. Guidelines of the International Headache Society for Real-World Evidence studies in migraine and cluster headache. Cephalalgia 2025;45:3331024251318016
   doi: 10.1177/03331024251318016. PMID 40095946
   Impact factor: 5.000

2. Sacco S, Ashina M, Diener HC, Haghdoost F, Lee MJ, Monteith TS, Jenkins B, Peres MFP, Pozo-Rosich P, Ornello R, Puledda F, Sakai F, Schwedt TJ, Terwindt G, Vaghi G, Wang SJ, Ahmed F, Tassorelli C. Setting higher standards for migraine prevention: A position statement of the International Headache Society. Cephalalgia 2025;45:333102451320608
   doi: 10.1177/03331024251320608. PMID 39980456
   Impact factor: 5.000

3. Gine-Cipres E, Torres-Ferrus M, Gallardo VJ, Alpuente A, Caronna E, Pozo-Rosich P (CA). Quality of Headache Management in Inpatients. Pain Management Nursing 2025:S1524-9042(24)00317-5
   doi: 10.1016/j.pmn.2024.12.006. PMID 39799047

4. Pozo-Rosich P (CA). Headache research in 2024: new data on migraine prevention. Lancet Neurol 2025;24:11-13
   doi: 10.1016/S1474-4422(24)00485-X. PMID 39706618
   Impact factor: 46.600

5. Gottschalk C, Gandhi P, Pozo-Rosich P, Christie S, Tassorelli C, Stokes J, Liu Y, Luo L, Nagy K, Trugman JM, Lipton RB. Effect of preventive treatment with atogepant on quality of life, daily functioning, and headache impact across the spectrum of migraine: Findings from three double-blind, randomized, phase 3 trials. Cephalalgia 2024;44:3331024241300305
   doi: 10.1177/03331024241300305. PMID 39648617
   Impact factor: 5.000

6. Pozo-Rosich P, García-Azorín D. Díaz-Cerezo S, Fernandez-Montoya J, de Paz HD, Nuñez M. Real-world experience of galcanezumab in the prevention of migraine in Spain: a systematic literature review. Front Neurol 2024;15:1502575. eCollection 2024
   doi: 10.3389/fneur.2024.1502475. PMID 39639987
   Impact factor: 2.700

7. Rosignoli C, Ornello R, Caponnetto V, Onofri A, Avaltroni S, Braschinsky M, Sved O, Gil-Gouveia R, Lampl C, Paungarttner J, Martelletti P, Wells-Gatnik WD, Martins IP, Mitsikostas D, Apostolakopoulou L, Nabaei G, Izge A, Narin DB, Pozo-Rosich P, Muñoz-Vendrell A, Prudenzano MP, Gentile M, Ryliskiene K, Vainaskiene J, Del Rio MS, Vernieri F, Iaccarino G, Waliszewka-Prosol M, Budrewicz S, Carnovali M, Katsarava Z, Sacco S. Resistant and refractory migraine – two different entities with different comorbidities? Results from the REFINE study. Journal Headache Pain 2024;25:212
   doi: 10.1186/s10194-024-01910-3. PMID 39627727
   Impact factor: 7.300

8. Ailani J, Lalla A, Halker Singh RB, Holle-Lee D, Nagy K, Kelton K, Piron C, Gandhi P, Pozo-Rosich P. Benefit-risk assessment based on number needed to treat and number needed to harm: Atogepant vs. calcitonin gene-related peptide monoclonal antibodies. Cephalalgia 2024;44:333102424199377
   doi: 10.1177/03331024241299377. PMID 39558612
   Impact factor: 5.000

9. Gonzalez-Martinez A, Ray JC, Haghdoost F, Ashraf U, Cerrahoglu ST, Dantes MC, Gosalia H, Hwang H, Kim JM, Lange KS, Jennysdotter Olofsgard F, Caronna E, Pozo-Rosich P (CA); International Headache Academy of the International Headache Society. Time and headache: Insights into timing processes in primary headache disorders for diagnosis, underlying pathophysiology and treatment implications. Cephalalgia 2024;44:3331024241297652
   doi: 10.1177/03331024241297652. PMID 39558611
   Impact factor: 5.000

10. Cammarota F, De Icco R, Vaghi G, Corrado M, Bighiani F, Martinelli D, Pozo-Rosich P, Goadsby PJ, Tassorelli C. High-frequency episodic migraine: Time for its recognition as a migraine subtype? Cephalalgia 2024;44:3331024241291578
    doi: 10.1177/03331024241291578. PMID 39434667
    Impact factor: 5.000

11. Sebastianelli G, Çimen Atalar A, Cetta I, Farham F, Fitzek M, Karatas-Kursun H, Kholodova M, Kukumägi K-H, Montisano DA, Onan D, Pantovic A, Skarlet J, Sotnikov D, Caronna E, Pozo-Rosich P (CA); International Headache Academy of the International Headache Society (IHS-iHEAD). Insights from triggers and prodromal symptoms on how migraine attacks start. The threshold hypothesis. Cephalalgia 2024;44:33331024241287224
    doi: 10.1177/03331024241287224. PMID 39380339
    Impact factor: 5.000

12. Elosua-Bayes I, Alpuente A, Melgarejo L, Caronna E, Torres-Ferrus M, Pozo-Rosich P (CA). Case series on monoclonal antibodies targeting calcitonin gene-related peptide in migraine patients during pregnancy: enhancing safety data. Cephalalgia 2024;44:3331024241273966.
    doi: 10.1177/03331024241273966. PMID 39314064
    Impact factor: 5.000

13. Membrilla JA, Alpuente A, Gomez-Dabo L, Garcia-Yu R, Mariño E, Diaz de Teran J, Pozo-Rosich P (CA). Code Headache: development of a protocol for optimizing headache management in the emergency room. Eur J Neurol 2024;31(12):e16484
    doi: 10.1111/ene.16484. PMID 39287050
    Impact factor: 4.500

14. Ihara K, Casillo F, Dahshan A, Genç H, Jusupova A, Karbozova K, Lee W, Chia Law Yi, Mavridis T, Park HK, Polat B, Unt TH, Vashchenko N, Zhantleuova A, Pozo-Rosich P, Schwedt TJ. Are we closer to achieving precision medicine for migraine treatment? A narrative review. Cephalalgia 2023;44:3331024241281518
    doi 10.1177/03331024241281518. PMID 39256924
    Impact factor: 5.000

15. Puledda F, Sacco S, Diener HC, Ashina M, Al-Khazali HM, Ashina S, Burstein R, Liebler E, Cipriani A, Chu MK, Cocores A, Dodd-Glover F, Ekizoglu E, Garcia-Azorin D, Göbel C, Goicochea MT, Hassan A, Hirata K, Hoffmann J, Jenkins B, Kamm K, Lee MJ, Ling YH, Lisicki M, Martinelli D, Monteith TS, Ornello R, Ozge A, Peres M, Pozo-Rosich P, Romanenko V, Schwedt TJ, Souza MNP, Takizawa T, Terwindt GM, Thuraiaiyah J, Togha M, Vandenbussche N, Wang SJ, Yu S, Tassorelli C. International Headache Society global practice recommendations for the preventive pharmacological treatment of migraine. Cephalalgia 2024;44:3331024241269735.
    doi: 10.1177/03331024241269735. PMID 39262214
    Impact factor: 5.000

16. Peres MFP, Sacco S, Pozo-Rosich P, Tassorelli C, Ahmed F, Burstein R, Ashina S, Uluduz D, Husoy AK, Steiner TJ. Migraine is the most disabling neurological disease among children and adolescents, and second after stroke among adults: a call to action. Cephalalgia 2024;44:3331024241267309
    doi 10.1177/03331024241267309. PMID 39197864
    Impact factor: 5.000

17. Pozo-Rosich P (CA), Alpuente A, Silberstein SD, Burstein R. Insights from 25 years of onabotulinumtoxinA in migraine – mechanisms and management. Nat Rev Neurol 2024;20:555-568
    doi: 10.1038/s41582-024-01002-5. PMID 39160284
    Impact factor: 28.200

18. Puledda F, Sacco S, Diener HC, Ashina M, Al-Khazali HM, Ashina S, Burstein R, Liebler E, Cipriani A, Chu MK, Cocores A, Dodd-Glover F, Ekizoglu E, Garcia-Azorin D, Göbel C, Goicochea MT, Hassan A, Hirata K, Hoffmann J, Jenkins B, Kamm K, Lee MJ, Ling YH, Lisicki M, Martinelli D, Monteith TS, Ornello R, Ozge A, Peres M, Pozo-Rosich P, Romanenko V, Schwedt TJ, Souza MNP, Takizawa T, Terwindt GM, Thuraiaiyah J, Togha M, Vandenbussche N, Wang SJ, Yu S, Tassorelli C. International Headache Society global practice recommendations for the acute pharmacological treatment of migraine. Cephalalgia 2024;44:3331024241252666
    doi:10.1177/03331024241252666. PMID 39133176
    Impact factor: 5.000

19. Schwedt TJ, Pradhan AA, Oshinsky ML, Brin MF, Rosen H, Lalvani N, Charles A, Ashina M, Phu Do T, Burstein R, Gelfand AA, Dodick DW, Pozo-Rosich P, Lipton RB, Ailani J, Szperka CL, Charleston IV L, Digre KB, Russo AF, Buse DC, Powers SW, Tassorelli C, Goadsby PJ, on behalf of the Headache Research Priorities Working Group Members. The headache research priorities: Research goals from the American Headache Society and an international multistakeholder expert group. Headache 2024;64:912-930
    doi: 10.1111/head.14797. PMID 39149968
    Impact factor: 5.400

20. Navarro-Perez MP, González-Quintanilla V, Muñoz-Vendrell A, Madrigal E, Alpuente A, Latorre G, Molina F, Monzon MJ, Medrano V, Garcia-Azorin D, Gonzalez-Oria C, Gago-Veiga A, Velasco F, Beltran I, Morollon N, Viguera J, Casas-Limon J, Rodriguez-Vico J, Cuadrado E, Irimia P, Iglesias F, Guerrero-Peral A, Belvis R, Pozo-Rosich P, Pascual J, Santos S. Long-term safety of onabotulinumtoxinA treatment in chronic migraine patients: a five-year retrospective study. Front Neurol 2024;15:1417831
    doi: 10.3389/fneur.2024.1417831. PMID 38938776
    Impact factor: 2.700

21. Qu K, Li MX, Yu P; International Headache Genetics Consortium; Wu BH, Shi M, Dong M. HMG-CoA reductase is a potential therapeutic target for migraine: a mendelian randomization study. Sci Rep 2024;14:12094
    doi: 10.1038/s41598-024-61628-9. PMID 38802400
    Impact factor: 3.800

22. Gomez-Dabó L, Caronna E, Mas-de-les-Valls R, Gallardo VJ, Alpuente A, Torres-Ferrus M, Pozo-Rosich P (CA). Effectiveness and safety of onabotulinumtoxinA in adolescent patients with chronic migraine. Toxins (Basel) 2024;16:221
    doi: 10.3390/toxins16050221. PMID 38787073
    Impact factor: 3.900

23. Caronna E, Gallardo VJ, Egeo G, Vázquez MM, Castellanos CN, Membrilla JA, Vaghi G, Rodríguez-Montolio J, Fabregat Fabra N, Sánchez-Caballero F, Jaimes Sánchez A, Muñoz-Vendrell A, Oliveira R, Gárate G, González-Osorio Y, Guisado-Alonso D, Ornello R, Thunstedt C, Fernández-Lázaro I, Torres-Ferrús M, Alpuente A, Torelli P, Aurilia C, Pére RL, Castrillo MJR, Icco R, Sances G, Broadhurst S, Ong HC, García AG, Campoy S, Sanahuja J, Cabral G, Beltrán Blasco I, Waliszewska-Prosół M, Pereira L, Layos-Romero A, Luzeiro I, Dorado L, Álvarez Escudero MR, May A, López-Bravo A, Martins IP, Sundal C, Irimia P, Lozano Ros A, Gago-Veiga AB, Juanes FV, Ruscheweyh R, Sacco S, Cuadrado-Godia E, García-Azorín D, Pascual J, Gil-Gouveia R, Huerta-Villanueva M, Rodriguez-Vico J, Viguera Romero J, Obach V, Santos-Lasaosa S, Ghadiri-Sani M, Tassorelli C, Díaz-de-Terán J, Díaz Insa S, Oria CG, Barbanti P, Pozo-Rosich P (CA); EUREkA study group. Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world. J Neurol Neurosurg Psychiatry 2024;95:927-937
    doi: 10.1136/jnnp-2023-333295. PMID 38777579
    Impact factor: 8.800

24. Li G, Duan S; International Headache Genetics Consortium, (IHGC), Zheng T, Zhu T, Qu B, Liu L, Liu Z. Genetic causal relationship between immune diseases and migraine: a Mendelian randomization study. Front Immunol 2024;15:1376698
    doi: 10.3389/fimmu.2024.1376698. PMID 38650934
    Impact factor: 5.700

25. Lipton RB, Nahas SJ, Pozo-Rosich P, Bilchik T, Mc Allister P, Finnegan M, Liu Y, Chalermpalanupap N, Dabruzzo B, Dodick DW. Sustained response to atogepant in episodic migraine: post hoc analyses of a 12-week randomized trial and a 52-week long-term safety trial. Journal Headache Pain 2024;25:83
    doi: 10.1186/s10194-024-01783-6. PMID 38773375
    Impact factor: 7.300

26. Belvis R, Irimia P, Gonzalez N, García-Ull J, Pozo-Rosich P, Lopez-Bravo A, Morollon N, Quintas S, Plana A, Baz PG, Tentor A, Gallego Artiles N, Leon FJ, Perez Martin M, Rivera I, Ramirez R, Colomina I, Lainez JM, Pascual J. Migraine treatment consensus of the Spanish Society of Neurology (SEN), Spanish Society of Family and Community Medicine (SEMFYC), Society of Primary Care Medicine (SEMERGEN) and Spanish Association of Migraine and Headache (AEMICE) on migraine treatment. Med Clin (Barc). 2024;S0025-7753(24)00137-4.
    doi: 10.1016/j.medcli.2024.02.006. PMID: 38643025

Impact factor: 2.600

27. Alpuente A, Gallardo VJ, Asskour L, Caronna E, Torres-Ferrus M, Pozo-Rosich P (CA). Dynamic fluctuations of salivary CGRP levels during migraine attacks: association with clinical variables and phenotypic characterization. Journal Headache Pain 2024;25:58.
    doi: 10.1186/s10194-024-01772-9. PMID: 38637736
    Impact factor: 7.300

28. Mitsikostas DD, Caronna E, De Tommaso M, Deligianni CI, Ekizoglu E, Bolay H, Göbel CH, Kristoffersen ES, Lampl C, Moro E, Pozo-Rosich P, Sellner J, Terwindt G, Irimia-Sieira P. Reply to the letter: Headaches during/after SARS-CoV-2 infection/vaccination can be primary and secondary as well as acute and chronic, by Finsterer J and Mehri S. Eur J Neurol 2024:e16308
    doi: 10.1111/ene.16308. PMID: 38628031
    Impact factor: 4.500

29. Alpuente A, Torres-Ferrus M, Caronna E, Pozo-Rosich P (CA). The state of the art on the use of patient reported outcomes in migraine. Curr Opin Neurol 2024;37:271-282
    doi: 10.1097/WCO.0000000000001267. PMID: 38529698
    Impact factor: 4.100

30. Pozo-Rosich P, Carmo M, Muñiz A, Armada B, Moya-Alarcón C, Pascual J. Migraine treatment: quo vadis? Real-word data study (2015-2022) in Spain. BMC Neurol 2024;24:107
    doi: 10.1186/s12883-024-03600-8. PMID: 38566063
    Impact factor: 2.200

31. Pozo-Rosich P (CA), Dolezil D, Paemelaire K, Stephen A, Stude P, Snellman J, Arkuszewski M, Stites T, Ritter S, Lopez Lopez C, Maca J, Ferraris M, Gil-Gouveia R. Early use of erenumab vs nonspecific oral migraine preventives. The APPRAISE randomized clinical trial. JAMA Neurology 2024:81(5):461-470
    doi: 10.1001/jamaneurol.2024.0368. PMID: 38526461
    Impact factor: 20.900

32. Irimia P, Santos-Lasaosa S, Pozo-Rosich P, Leira R, Pascual J, Lainez JM. Eptinezumab for the preventive treatment of episodic and chronic migraine: a narrative review. Front Neurol 2024;15:1355877
    doi: 10.3389/fneur.2024.1355877. eCollection 2024.PMID: 38523607
    Impact factor: 2.700

33. Ashina H, Diener HC, Tassorelli C, Scher AI, Lipton RB, Pozo-Rosich P, Sinclair AJ, Chong CD, Finkel AD, Ashina M, Schwedt TJ, Dodick DW, Terwindt GM. Guidelines of the International Headache Society for controlled trials of pharmacological preventive treatment for persistent post-traumatic headache attributed to mild traumatic brain injury. Cephalalgia 2024;44:3331024241234068.
    doi: 10.1177/03331024241234068. PMID: 38518177
    Impact factor: 5.000

34. Pozo-Rosich P (CA), Poveda JL, Crespo C, Martinez A, Rodriguez JM, Irimia P. Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis. Journal Headache Pain 2024;25:40
    doi: 10.1186/s10194-024-01747-w.PMID: 38491460
    Impact factor: 7.300

35. Ikumi N, Marti-Marca A, Torre-Suñe A, Cerda-Company X, Vila-Ballo A, Gallardo VJ, Caronna E, Alpuente A, Pozo-Rosich P. Quantifying sensory thresholds along the migraine cycle. Quantifying sensory thresholds along the migraine cycle: an exploratory longitudinal study. Cephalalgia 2024;3331024241230279
    doi: 10.1177/03331024241230279.PMID: 38416486
    Impact factor: 5.000

36. Mitsikostas DD, Caronna E, de Tomasso M, Deligianni CI, Ekizoglu E, Bolay H, Göbel CH, Kristoffersen ES, Lampl C, Moro E, Pozo-Rosich P, Sellner J, Terwindt G, Irimia P. Headaches and facial pain attributed to SARS-CoV-2 infection and vaccination: a systematic review. European Journal Neurology 2024;00:e16251.
    doi 10.1111/ene.16251. PMID: 38415282
    Impact factor: 4.500

37. Goadsby PJ, Evers S, Gelfand AA, Lipton RB, May A, Pozo-Rosich P, Schoenen J, Schwedt TJ, Tassorelli C, Terwindt G, Wang SJ. International Classification of Headache Disorders-4 – Work in progress 1. Cephalalgia 2024 44(2):3331024241233937
    doi: 10.1177/03331024241233937.PMID: 38388354
    Impact factor: 5.000

38. Tassorelli C, Nagy K, Pozo-Rosich P, Lanteri-Minet M, Sacco S, Nezádal T, Guo H, De Abreu Ferreira R, Forero G, Trugman JM. Safety and efficacy for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial. Lancet Neurol 2024;S1474-4422(24)00025-5
    doi: 10.1016/S1474-4422(24)00025-5. Epub 2024 Feb 13.PMID: 38364831
    Impact factor: 46.500

39. Lazaro-Hernandez C, Caronna E, Rosell-Mirmi J, Gallardo VJ, Alpuente A, Torres-Ferrus M, Pozo-Rosich P (CA). Early and annual projected savings from anti-CGRP monoclonal antibodies in migraine prevention: a cost-benefit analysis in the working-age population. Journal Headache Pain 2024;25:21
    doi: 10.1186/s10194-024-01727-0.PMID: 38347485
    Impact factor: 7.300

40. Caronna E, Alpuente A, Torres-Ferrus M, Pozo-Rosich P (CA). CGRP monoclonal antibodies and CGRP receptor antagonists (gepants) in migraine prevention. Handbook Clinical Neurology 2024;199:107-124
    doi: 10.1016/B978-0-12-823357-3.00024-0.PMID: 38307640

41. Torres- Ferrus M, Gallardo VJ, Alpuente A, Caronna E, Gine-Cipres E, Pozo-Rosich P (CA). Improvement of migraine depressive symptoms is not related to headache frequency: exploring the impact of anti-CGRP therapies. Cephalalgia 2024;44:3331024231222923
    doi: 10.1177/03331024231222923.PMID: 38307497
    Impact factor: 5.000

42. Pozo-Rosich P (CA), Ashina M, Tepper SJ, Jensen S, Boserup LP, Josiassen MK, Sperling B. Eptinezumab Demonstrated Efficacy Regardless of Prior Preventive Migraine Treatment Failure Type: Post Hoc Analyses of the DELIVER Study. Neurol Ther. 2024;13:339-353.
    doi: 10.1007/s40120-023-00575-5. PMID: 38236314.
    Impact factor: 4.000

43. Yu S, Zhou J, Luo G, Xiao Z, Ettrup A, Jansson G, Florea I, Ranc K, Pozo-Rosich P. Efficacy and safety of eptinezumab in patients with chronic migraine and medication-overuse headache: a randomized, double-blind, placebo-controlled study. BMC Neurol 2023;23:441
    doi: 10.1186/s12883-023-03477-z.PMID: 38102535
    Impact factor: 2.200

44. Ashina M, Mitsikostas DD, Amin FM, Koturk P, Schankin CJ, Sahin G, Pozo-Rosich P, Dorman PJ, Nezadal T, Poole AC, Martins IP, Sumelahti ML, Ramirez Campos V, Ahn AH, Lyras L, Tassorelli C. Real-world effectiveness of fremanezumab for the preventive treatment of migraine: interim analysis of the pan-European, prospective, observational, phase 4 PEARL study. Cephalalgia 2023;43:3331024231214987
    doi: 10.1177/03331024231214987.PMID: 37987641
    Impact factor: 5.000

45. Lipton RB, Pozo-Rosich P, Orr SL, Reed ML, Fanning KM, Dabruzzo B, Buse DC. Impact of monthly headache days on migraine-related quality of life: results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study. Headache 2023
    doi: 10.1111/head.14629. Epub 2023 Oct 5.PMID: 37795746
    Impact factor: 5.400

46. Melgarejo L, Caronna E, Rosell-Mirmi J, Elosua-Bayés I, Alpuente A, Torres-Ferrus M, Gallardo VJ, Pozo-Rosich P (CA). Migraine worsening after COVID-19 and COVID-19 vaccination: are we facing a nocebo effect? Eur J Neurol 2023
    doi: 10.1111/ene.16058. Epub 2023 Oct 4.PMID: 37791410
    Impact factor: 4.500

47. Kim SA, Choi SY, Youn MS, Pozo-Rosich P, Lee MJ. Epidemiology, burden and clinical spectrum of cluster headache: a global update. Cephalalgia 2023;43:
    doi: 10.1177/03331024231201577.PMID: 37728577
    Impact factor: 5.000

48. Labastida-Ramirez A, Caronna E, Gollion C, Stanyer E, Dapkute A, Braniste D, Naghshineh H, Meksa L, Chkhitnidze N. Gudadze T, Pozo-Rosich P, Burstein R, Hoffmann J. Mode and site of action of therapies targeting CGRP signaling. Journal Headache Pain 2023;24:125
    doi: 10.1186/s10194-023-01644-8.PMID: 37691118
    Impact factor: 7.300

49. Gomez-Dabo L, Melgarejo-Martinez L, Caronna E, Pozo-Rosich P (CA). Headache in COVID-19 and long COVID: to know facts for clinical practice. Curr Neurol Neurosci Rep 2023 Oct;23(10):551-560.
    doi: 10.1007/s11910-023-01296-w. Epub 2023 Sep 4.PMID: 37665495
    Impact factor: 4.800

50. Molan SP, Fraser CL, Digre KB, Diener HC, Lipton RB, Juhler M, Miller NR, Pozo-Rosich P, Togha M, Brock K, Dinkin MJ, Chan CKM, Tassorelli C, Sinclair AJ, Terwindt GM, Jensen RH. Guidelines of the International Headache Society for Controlled Clinical Trials in Idiopathic Intracranial Hypertension. Cephalalgia 2023;43:3331024231197118
    doi: 10.1177/03331024231197118.PMID: 37661711
    Impact factor: 5.000

51. De Boer I, Ambrosini A, Halker Singh RB, Baykan B, Buse DC, Tassorelli C, Jensen RH, Pozo-Rosich P, Terwindt GM; International Headache Society Women’s Leadership Forum. Harassment in the headache field: a global web-based cross-sectional survey. Cephalalgia 2023;43(8)
    doi: 10.1177/03331024231193099.PMID: 37652444
    Impact factor: 5.000

52. Buse DC, Pozo-Rosich P, Dupont-Benjamin L, Balkaran BL, Lee L, Jauregui A, Gandhi P, Parikh M, Reuter U. Impact of headache frequency and preventive medication failure on quality of life, functioning, and costs among individuals with migraine across several European countries: need for effective preventive treatment. Journal Headache Pain 2023;24:115
    doi: 10.1186/s10194-023-01655-5.PMID: 37612633
    Impact factor: 7.300

53. Gonzalez R, Aymerich FX, Alberich M, Caronna E, Gallardo VJ, Pozo-Rosich P, Rovira A, Pareto D. Estimation of the density of veins from susceptibility-weighted imaging by using the Mamdani fuzzy-type rule-based system. Investigating the neurovascular coupling in migraine. Neuroimage Clin 2023;39:103489
    doi: 10.1016/j.nicl.2023.103489. PMID: 37611372
    Impact factor: 3.400

54. Alpuente A, Torre-Sune A, Caronna E, Gine-Cipres E, Torres-Ferrus M, Pozo-Rosich P (CA). Impact of anti-CGRP monoclonal antibodies on migraine attack accompanying symptoms: a real-world evidence study. Cephalalgia 2023;43:3331024231177636
    doi: 10.1177/03331024231177636.PMID: 37555331
    Impact factor: 5.000

55. Vila-Pueyo M, Gliga O, Gallardo VJ, Pozo-Rosich P. The role of glial cells in different phases of migraine: lessons from preclinical studies. International Journal of Molecular Sciences 2023;24:12553
    doi: 10.3390/ijms241612553.PMID: 37628733
    Impact factor: 4.900

56. Marti-Marca A, Vila-Ballo A, Cerda-Company X, Ikumi N, Torres-Ferus M, Caronna E, Gallardo VJ, Alpuente A, Torralba Cuello M, Soto-Faraco S, Pozo-Rosich P (CA). Exploring sensory sensitivity, cortical excitability, and habituation in episodic migraine, as a function of age and disease severity, using pattern-reversal task. The Journal of Headache and Pain 2023;24:104
    doi: 10.1186/s10194-023-01618-w.PMID: 37545005
    Impact factor: 7.300

57. Pozo-Rosich P (CA), Ailani J, Ashina M, Goadsby PJ, Lipton RB, Reuter U, Guo H, Schwefel B, Lu K, Boinpally R, Miceli R, De Abreu Ferreira R, McCusker E, Yu SY, Severt L, Finnegan M, Trugman JM. Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023:S0140-6736(23)01049-8
    doi: 10.1016/S0140-6736(23)01049-8. Epub 2023 Jul 26.PMID: 37516125
    Impact factor: 98.400

58. May A, Evers S, Goadsby PJ, Leone M, Manzoni GC, Pascual J, Carvalho V, Romoli M, Aleksovska K, Pozo-Rosich P, Jensen RH, European Academy of Neurology Task Force. European Academy of Neurology Guidelines on the treatment of cluster headache. Eur J Neurol 2023.
    doi: 10.1111/ene.15956. Epub 2023 Jul 28.PMID: 37515405
    Impact factor: 4.500

59. Winsvold BS, Harder AVE, Ran C, Chalmer MA, Dalmasso MC, Ferkingstad E, et al. Cluster headache genome-wide association study and meta-analysis identifies eight loci and implicates smoking as a causal risk factor. Ann Neurol 2023;94:713-726
    doi: 10.1002/ana.26743. Epub 2023 Aug 7.PMID: 37486023
    Impact factor: 8.100

60. He Q, Wang W, Xiong Y, Tao C, Ma L, Ma J, You C, International Headache Genetics Consortium. A causal effect of gut microbiota in the development of migraine. J Headache Pain 2023;24:90.
    doi: 10.1186/s10194-023-01609-x.PMID: 37460956
    Impact factor: 7.300

61. Mitsikostas DD, Waeber C, Sanchez-del-Rio M, Raffaelli B, Ashina H, Maassen van den Brink A, Andreou A, Pozo-Rosich P. Rapoport A, Ashina M, Moskowitz MA. The 5-HT1F receptor as the target of ditans in migraine – from bench to bedside. Nat Rev Neurol 2023;19:489-505
    doi: 10.1038/s41582-023-00842-x. Epub 2023 Jul 12.PMID: 37438431
    Impact factor: 28.200

62. Zhang W, Zhang L, Yang L, Xiao C, Wu X, Yan P, Cui H, Yang C, Zhu J, Wu X, Tang M, Wang Y, Chen L, Liu Y, Zou Y, Zhang L, Yang C, Yao Y, Li J, Liu Z, Zhang B, Jiang X, International Headache Genetics Consortium. Migraine, chronic kidney disease and kidney function: observational and genetic analyses. Hum Genet 2023;142:1185-1200
    doi: 10.1007/s00439-023-02575-9. Epub 2023 Jun 12.PMID: 37306871
    Impact factor: 3.800

63. Muñoz-Vendrell A, Campoy S, Caronna E, Alpuente A, Torres-Ferrus M, Nieves Castellanos C, Olivier M, Campdelacreu J, Prat J, Camiña Muñiz J, Molina Martinez FJ, Minguez-Olaondo A, Ruibal Salgado M, Santos Lasaosa S, Navarro Perez MP, Morollon N, Lopez Bravo A, Cano Sanchez LM, Garcia-Sanchez SM, Garcia-Ull J, Rubio-Flores L, Gonzalez-Martinez A, Quintas S, Echevarria Iñiguez A, Gil Luque S, Castro-Sanchez MV, Adell Ortega V, Garcia Alhama J, Berrocal-Izquierdo N, Belvis R, Diaz-Insa S, Pozo-Rosich P, Huerta Villanueva M. Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients. Journal Headache Pain 2023;24:63
    doi: 10.1186/s10194-023-01585-2.PMID: 37268904
    Impact factor: 7.300

64. Ashina M, Lanteri-Minet M, Ettrup A, Christoffersen CL, Josiassen MK, Phul R, Sperling B, Pozo-Rosich P. Efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures: subgroup analysis of the randomized, placebo-controlled DELIVER study. Cephalalgia 2023;43: 3331024231170807
    doi: 10.1177/03331024231170807.PMID: 37125484
    Impact factor: 5.000

65. Torres-Ferrus M, Gallardo VJ, Alpuente A, Caronna E, Gine-Cipres E, Pozo-Rosich P (CA). Patterns of response to anti-CGRP monoclonal antibodies during the first 6-months of treatment in resistant migraine patients: impact on outcome. Eur J Neurol 2023;30:1937-1944
    doi: 10.1111/ene.15816. Epub 2023 Apr 26.PMID: 37038303
    Impact factor: 4.500

66. Rovira-Simon J, Sales-i-Coll M, Pozo-Rosich P, Hueto-Madrid JA, Canovas Paradell R, Ochoa de Echagüen Aguilar A, Carbonell-Cobo M, de Castro R, Shaw G. The green surgical block 4.0: automation of the operating theatre’s climate conditions through a real-time patient-flow solution. Future Healthcare Journal 2023;10:1-4
    Doi:10.7861/fhj.2022-0142. PMID 37786502
    Impact factor: 1.200

67. Haghdoost F, Puledda F, Garcia-Azorin D, Huessler EM, Messina R, Pozo-Rosich P. Evaluating the efficacy of CGRP mAbs and gepants and network meta-analysis of phase 3 randomised controlled trials. Cephalalgia 2023;3331024231159366
    doi: 10.1177/03331024231159366.PMID: 36855951
    Impact factor: 5.000

68. Gallardo VJ, Gomez-Galvan JB, Asskour L, Torres-Ferrus M, Alpuente A, Caronna E, Pozo-Rosich P (CA). A study of differential microRNA expression profile in migraine: the microMIG exploratory study. Journal Headache Pain 2023;24(1):11
    doi: 10.1186/s10194-023-01542-z.PMID: 36797674
    Impact factor: 7.300

69. Zhao L, Zhao W: International Headache Genetics Consortium; Cao J, Tu Y. Causal relationships between migraine and microstructural white matter: a Mendelian randomization study. Journal Headache Pain 2023;24(1):10
    doi: 10.1186/s10194-023-01550-z.PMID: 36793015
    Impact factor: 7.300

70. Vila-Pueyo M, Cuenca-Leon E, Queiros AC, Kulis M, Sintas C, Cormand B, Martin-Subero JI, Pozo-Rosich P, Fernandez-Castillo N, Macaya A. Genome-wide DNA methylation analysis in an antimigraine-treated preclinical model of cortical spreading depolarization. Cephalalgia 2023;43: 3331024221146317.
    doi: 10.1177/03331024221146317.PMID: 36759321

Impact factor: 5.000

71. Gallardo VJ, Vila-Pueyo M, Pozo-Rosich P (CA). The impact of epigenetic mechanisms in migraine: Current knowledge and future directions. Cephalalgia 2023;43: 3331024221145916
    doi: 10.1177/03331024221145916.PMID: 36759209
    Impact factor: 5.000

72. Welander NZ, Rukh G, Rask-Andersen M, Harder AVE, International Headache Genetics Consortium, van den Maagdenberg AMJM, Schiöth HB, Mwinyi J. Migraine, inflammatory bowel disease and celiac disease: a mendelian randomization study. Headache 2023;63::642-651.
    doi: 10.1111/head.14470. PMID: 36705326
    Impact factor: 5.400

73. Caronna E, Pozo-Rosich P (CA). Virtual issue: COVID-19 and headache. Headache 2023;63:183-184
    doi: 10.1111/head.14464. Epub 2023 Jan 12.PMID: 36633206
    Impact factor: 5.400

74. Caronna E, van den Hoek TC, Bolay H, Garcia-Azorin D, Gago-Veiga AB, Valeriani M, Takizawa T, Messlinger K, Shapiro RE, Goadsby PJ, Ashina M, Tassorelli C, Diener HC, Terwindt GM, Pozo-Rosich P (CA). Headache attributed to SARS-CoV-2 infection, vaccination and the impact on primary headache disorders of the COVID-19 pandemic: a comprehensive review. Cephalalgia 2023;43:3331024221131337.
    doi: 10.1177/03331024221131337.PMID: 36606562
    Impact factor: 5.000

75. Lipton RB, Pozo-Rosich P, Blumenfeld A, Li Y, Severt L, Stokes JT, Creutz L, Gandhi P, Dodick D. Effect of atogepant for preventive migraine treatment on Patient-Reported Outcomes in the randomized, double-blind, phase 3 ADVANCE trial. Neurology 2022; Feb 21;100(8):e764-e777.
    doi: 10.1212/WNL.0000000000201568. PMID: 36396451
    Impact factor: 7.700

76. Altamura C, Ornello R, Ahmed F, Nero A, Miscio AM, Santoro A, Alpuente A, Russo A, Silvestro M, Cevoli S, Brunelli N, Grazzi L, Baraldi C, Guerzoni S, Andreou AP, Lambru G, Frattale I, Kamm K, Ruscheweyh R, Russo M, Torelli P, Filatova E, Latysheva N, Gryglas-Dworak A, Straburzynski M, Butera C, Colombo B, Filippi M, Pozo-Rosich P, Martelletti P, Sacco S, Vernieri F. OnabotulinumtoxinA in elderly patients with chronic migraine: insights from a real-life European multicenter study. J Neurol 2022,270(2):986-994.
    doi: 10.1007/s00415-022-11457-5. PMID: 36326890
    Impact factor: 4.900

77. Membrilla JA, Torres-Ferrus M, Alpuente A, Caronna E, Pozo-Rosich P (CA). Efficacy and safety of galcanezumab as a treatment of refractory episodic and chronic cluster headache: case series and narrative review. Headache 2022;62:1395-1405.
    doi: 10.1111/head.14404. Epub 2022 Nov 2.PMID: 36321947
    Impact factor: 5.000

78. Pozo-Rosich P (CA), Dodick DW, Esttrup A, Hirman J, Cady R. Shift in diagnostic classification of migraine after initiation of preventive treatment with eptinezumab: post hoc anaylsis of the PROMISE studies. BMC Neurology 2022;22:394.
    doi: 10.1186/s12883-022-02914-9.PMID: 36284281
    Impact factor: 2.600

79. Sacco S, Lampl C, Amin FM, Braschinsky M, Deligianni C, Uludüz S. Versijpt J, Ducros A, Gil-Gouveia R, Katsarava Z, Maetelletti P, Ornello R, Raffaelli B, Boucherie DM, Pozo-Rosich P, Sanchez-del-Rio M, Sinclair A, Maassen van den Brink A, Reuter U. European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure. Journal Headache Pain 2022;23:133
    doi: 10.1186/s10194-022-01502-z.PMID: 36224519
    Impact factor: 7.400

80. Ornello R, Baraldi C, Ahmed F, Negro A, Miscio AM, Santoro A, Alpuente A, Russo A, Silvestro M, Cevoli S, Brunelli N, Vernieri F, Grazzi L, Pani L, Andreou A, Lambru G, Frattale I, Kamm K, Ruscheweyh R, Russo M, Torelli P, Filatova E, Latysheva N, Gryglas-Dworak A, Straburzynski M, Bultera C, Colombo B, Filippi M, Pozo-Rosich P, Martelletti P, Guerzoni S, Sacco S. Excellent response to onabotulinumtoxinA: different definitions, different predictors. Int J Environ Res Public Health 2022;19/17):10975
    doi: 10.3390/ijerph191710975.PMID: 36078699
    Impact factor: 4.614

81. De Boer I, Ambrosini A, Halker Singh RB. Baykan B, Buse DC, Tassorelli C, Jensen RH, Pozo-Rosich P, Terwindt GM, International Headache Society Women’s Leadership Forum. Perceived barriers to career progression in the headache field: a global web-based cross-sectional survey. Cephalalgia 2022; 42(14):1498-1509.
    doi: 10.1177/03331024221123081.PMID: 36071614
    Impact factor: 4.900

82. Gallardo VJ, Shapiro RE, Caronna E, Pozo-Rosich P (CA). The relationship of headache as a symptom to COVID-19 survival: a systematic review and meta-analysis of survival of 43,169 inpatients with COVID-19. Headache 2022; 62(8):1019-1028.
    doi: 10.1111/head.14376. PMID: 36053077
    Impact factor: 5.000

83. Kristensen MGH, Do TP, Pozo-Rosich P, Amin FM. Interest in and exposure to headache disorders among neurology residents in Denmark: a nationwide cross-sectional survey. Acta Neurol Scand 2022; 146(5):568-572.
    doi: 10.1111/ane.13681. PMID: 36004408
    Impact factor: 3.500

84. Alpuente A, Gallardo VJ, Asskour L, Caronna E, Torres-Ferrus M, Pozo-Rosich P (CA). Salivary CGRP and erenumab treatment response: towards precision medicine in migraine. Ann Neurol 2022;92:846-859
    doi: 10.1002/ana.26472. PMID: 36054144
    Impact factor: 11.200

85. Gallardo VJ, Alpuente A, Pozo-Rosich P (CA). Association of a cyclical migraine phenotype with disease progression: a one-year time series analysis. Neurology 2022;99(12):e1326-e1334.
    doi: 10.1212/WNL.0000000000200887. PMID: 35953289
    Impact factor: 10.100

86. Ikumi N, Cerda-Company X, Marti-Marca A, Vila-Ballo A, Caronna E, Gallardo VJ, Pozo-Rosich P (CA). Avoidance behaviour modulates but does not condition phonophobia in migraine. Cephalalgia 2022;42(13):1305-1316.
    doi: 10.1177/03331024221111772. PMID: 35815637
    Impact factor: 4.900

87. Steiner TJ, Terwindt GM, Katsarava Z, Pozo-Rosich P, Gantenbein AR, Roche SL, Dell’Agnello G, Tassorelli C. Migraine-attributed burden, impact and disability, and migraine-impacted quality of life: Expert consensus on definitions from a Delphi process. Cephalalgia 2022;42:1287-1396
    doi: 10.1177/03331024221110102. Epub 2022 Jul 5.PMID: 35791285
    Impact factor: 4.900

88. Ashina M, Lanteri-Minet M, Pozo-Rosich P, Ettrup A, Christoffersen CL, Josiassen MK, Phul R, Sperling B. Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol 2022;21(7):597-607
    doi: 10.1177/03331024221110102. Epub 2022 Jul 5.PMID: 35791285
    Impact factor: 48.000

89. Vilà-Balló A, Marti-Marca A, Torralba Cuello M, Soto-Faraco S, Pozo-Rosich P. The influence of temporal unpredictability on the electrophysiological mechanisms of neural entrainment. Psychophysiology 2022:e14108
    doi: 10.1111/psyp.14108. PMID: 35678104
    Impact factor: 3.700

90. Mitchell BL, Diaz-Torres S, Bivol S, Cuella-Partida G; International Headache Genetics Consortium; Gerring ZF, Martin NG, Medland SE, Grasby KL, Nyholt DR, Renteria ME. Elucidating the relationship between migraine risk and brain structure using genetic data. Brain 2022;145:3214-3224
    doi: 10.1016/S1474-4422(22)00185-5.PMID: 35716692
    Impact factor: 14.500

91. Lipton RB, Pozo-Rosich P, Blumenfeld AM, Dodick DW, McAllister P, Li Y, Lu K, Dabruzzo B, Miceli R, Severt L, Finnegan M, Trugman JM. Rates of response to atogepant for migraine prophylaxis among adults: a secondary analysis of a randomized clinical trial. JAMA Netw Open 2022;5(6):e2215499
    doi: 10.1001/jamanetworkopen.2022.15499.PMID: 35675076
    Impact factor: 13.800

92. Caronna E, Pozo-Rosich P (CA). Twenty twenty…two: Headache and COVID-19. Headache 2022; 62(6):648-649.
    doi: 10.1111/head.14330. PMID: 35670131
    Impact factor: 5.000

93. Santos-Lasaosa S, Belvis R, Cuadrado ML, Diaz-Insa S, Gago-Veiga A, Guerrero-Peral AL, Huerta M, Irimia P, Lainez JM, Latorre G, Leira R, Pascual J, Porta-Etessam J, Sanchez del Rio M, Viguera J, Pozo-Rosich P. Calcitonin gene-related peptide in migraine: from pathophysiology to treatment. Neurologia 2022;37(5):390-402
    doi: 10.1016/j.nrleng.2019.03.025. PMID: 35672126
    Impact factor: 3.900

94. Rovira-Simon J, Sales-i-Coll M, Pozo-Rosich P, Hueto-Madrid JA, Canovas Paradell R, Ochoa de Echagüen Aguilar A, Carbonell-Cobo M, de Castro R, Shaw G. Surgical block 4.0: a digital intervention based on a real-time location patient-flow solution to support the automation of surgical pathways. Future Healthcare Journal 2022;9:194-199
    doi: 10.7861/fhj.2022-0005.PMID: 35928182
    Impact factor: 0.900

95. Schwedt TJ, Tassorelli C, Silberstein SD, Szperka CL, Kurth T, Pozo-Rosich P, Amin FM, Lipton RB, Dodick DW, Ashina M, Diener HC, Terwindt GM. Guidelines of the International Headache Society for Clinic-Based Headache Registries, 1^st Cephalalgia 2022 42(11-12):1099-1115.
    doi: 10.1177/03331024221099035. PMID: 35514209
    Impact factor: 4.900

96. Mohamad Safiai NI, Mohamad NA, Basri H, Inche Mat LN, Hoo FK, Abdul Rasjid AM, Yusof Khan AHK, Loh WC, Baharin J, Fernandez A, Samsudin IN, Mohamed MH, Ching SM, Lee KW, Ramachandran V, Pozo-Rosich P, Wan Sulaiman WA. High-frequency repetitive trascranial magnetic stimulation at dorsolateral prefrontal cortex for migraine prevention: a systematic review and meta-analysis. Cephalalgia 2022;42:1071-1085.
    doi: 10.1177/03331024221092423. Epub 2022 Apr 17.PMID: 35435045
    Impact factor: 4.900

97. Pozo-Rosich P, Detke HC, Wang S, Dolezil D, Li LQ. Aurora SK, Reuter U. Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study. Curr Med Res Opin 2022;38(5):731-742.
    doi: 10.1080/03007995.2022.2059975. Epub 2022 Apr 15.PMID: 35392739
    Impact factor: 2.300

98. Pozo-Rosich P. Board Walk – April 2022. Cephalalgia 2022;42:427-429
    doi: 10.1177/03331024211070712. PMID: 35383491
    Impact factor: 4.900

99. Rovira-Simon J, Sales-i-Coll M, Pozo-Rosich P, Gates D, Patt C, Hennessey I, Emery L, Hueto-Madrid JA, Carbonell-Cobo M, Garcia-Cuyas F, Moz M, Chaudry Z, Shaw G. Introduction to the cognitive hospital. Future Healthcare J 2022;9:34-40
    doi: 10.7861/fhj.2021-0016.PMID: 35372780
    Impact factor: 0.900

100. Garcia-Azorin D, Layos-Romero A, Porta-Etessam J, Membrilla JA, Caronna E, Gonazalez-Martinez A, Mencia AS, Segura T, Gonzalez-Garcia N, Diaz de Teran J, Gallardo VJ, Gago-Veiga AB, Ballve A, Trigo-Lopez J, Sastre-Real A, Llaurado A, Cornejo A, de Lorenzo I, Guerrero-Peral A, Pozo-Rosich P. Post-COVID-19 persistent headache: a multicentric 9-months follow-up study of 905 patients. Cephalalgia 2022;42:804-809.
     doi: 10.1177/03331024211068074. Epub 2022 Feb 15.PMID: 35166156
     Impact factor: 4.900

101. Alpuente A, Gallardo VJ, Caronna E, Torres-Ferrus M, Pozo-Rosich P (CA). In search of a gold standard patient-reported outcome measure to use in the evaluation and treatment-decision making in migraine prevention. A real-world evidence study. Journal Headache Pain 2021;22:151
     doi: 10.1186/s10194-021-01366-9. PMID: 34903177
     Impact factor: 8.588

102. Caronna E, Pozo-Rosich P (CA). Headache as a symptom of COVID-19: narrative review of 1-year research. Current Pain and Headache Reports 2021;25:73
     doi: 10.1007/s11916-021-00987-8. PMID: 34766205
     Impact factor: 3.904

103. Halker Singh RB, Bobker SM, Roberts JL, Charleston L 4^th, Robbins MS, Pradhan A, Sprenger T, Pozo-Rosich P, Orr L, Powers SW, Houle TT, Turner DP, Gelfand AA. Advancing our commitment to our peer reviewers. Headache 2021;61(9):1299-1301.
     doi: 10.1111/head.14211. Epub 2021 Oct 13.PMID: 34643953
     Impact factor: 5.311

104. Pozo-Rosich P (CA), Lucas C, Watson DPB, Gaul C, Ramsden E, Ritter S, Martelletti O, Snellman J. Burden of migraine in patients with preventive treatment failure attending European Headache Specialist Centers: Real-World Evidence from the BECOME study. Pain Ther 2021;10(2):1691-1708.
     doi: 10.1007/s40122-021-00331-3. PMID: 34643891
     Impact factor: 3.960

105. Caronna E, Gallardo VJ, Alpuente A, Torres-Ferrus M, Pozo-Rosich P (CA). Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months. Journal Headache Pain 2021;22:120
     doi: 10.1186/s10194-021-01328-1.PMID: 34620085
     Impact factor: 8.588

106. Alpuente A, Gallardo VJ, Asskour L, Caronna E, Torres-Ferrus M, Pozo-Rosich P (CA). Salivary CGRP can monitor the different migraine phases: CGRP (in)dependent attacks. Cephalalgia 2022;42:186-196
     doi: 10.1177/03331024211040467. PMID: 34601944
     Impact factor: 4.900

107. Gallardo VJ, Alpuente A, Cerda-Company X, Torres-Ferrus M, Sanchez del Rio M, Lainez JM, Leira R, Trochet J, Pozo-Rosich P (CA). The impact of a digital platform on migraine patient-centered outcome research. Evaluation of midolordecabeza.org, a headache website in Spanish. Headache 2021;61:1403-1410.
     doi: 10.1111/head.14225. Epub 2021 Oct 3.PMID: 34601726
     Impact factor: 5.311

108. Ornello R, Ahmed F, Negro A, Miscio AM, Santoro A, Alpuente A, Russo A, Silvestro M, Cevoli S, Brunelli N, Vernieri F, Grazzi L, Baraldi C, Guerzoni S, Andreou AP, Lambru G, Kamm K, Ruscheweyh R, Russo M, Torelli P, Filatova E, Latysheva N, Gryglas-Dworak A, Straburzynski M, Butera C, Colombo B, Filippi M, Pozo-Rosich P, Marterlletti P, Sacco S. Is there a gender difference in the response to onabotulinumtoxinA in chronic migraine? Insights from a Real-Life European Multicenter Study on 2879 patients. Pain Ther 2021; 10(2):1605-1618.
     doi: 10.1007/s40122-021-00328-y. PMID: 34564833
     Impact factor: 3.960

109. Caronna E, Alpuente A, Torres-Ferrus M, Pozo-Rosich P (CA). Toward a better understanding of persistent headache after mild COVID-19: Three migraine-like yet distinct scenarios. Headache 2021;10(2):1605-1618.
     doi: 10.1007/s40122-021-00328-y. PMID: 34564833
     Impact factor: 5.311

110. Caronna E, Gallardo VJ, Alpuente A, Torres-Ferrus M, Pozo-Rosich P (CA). Epidemiology, work and economic impact of migraine in a large hospital cohort: time to raise awareness and promote sustainability. J Neurol 2022; 2022 Mar;269(3):1456-1462.
     doi: 10.1007/s00415-021-10715-2. PMID: 34282471
     Impact factor: 6.000

111. Torres-Ferrus M, Pareto D, Gallardo VJ, Cuberas-Borros G, Alpuente A, Caronna E, Vila-Ballo A, Lorenzo-Bosquet C, Castell-Conesa J, Rovira A, Pozo-Rosich P (CA). Cortical metabolic and structural differences in patients with chronic migraine. An exploratory 18-FDG-PET and MRI study. Journal Headache Pain 2021;22(1):75
     doi: 10.1186/s10194-021-01289-5.PMID: 34273945
     Impact factor: 8.588

112. Belvis R, Irimia P, Pozo-Rosich P, Gonzalez-Oria C, Cano A, Viguera J, Sanchez B, Beltran I, Oterino A, Cuadrado E, Gomez-Camello A, Alberte-Woodward M, Jurado C, Oms T, Ezpeleta D, de Teran JD, Morollon N, Latorre G, Torres-Ferrus M, Alpuente A, Lamas R, Toledano C, Leira R, Santos S, Sanchez del Rio MS. MAB-MIG: registry of the Spanish Neurological Society of erenumab for migraine prevention. Journal Headache Pain 2021;22(1):74
     doi: 10.1186/s10194-021-01267-x. PMID: 34273947
     Impact factor: 8.588

113. Harder AVE, Winsvold BS, Noordam R, Vijhuizen LS, Borte S, Kogelman LJA, de Boer I, Tronvik E, Rosendaal FR, Willems van Dijk K, O’Connor E, Fourier C, Thomas LF, Kristoffersen ES; Cluster Headache Genetics Working Group, Fronczek R, Pozo-Rosich P, Jensen RH, Ferrari MD, Hansen TF, Zwart JA, Terwindt GM, van den Maagdenberg AMJM. Genetic susceptibility loci in genomewide association study of cluster headache. Ann Neurol 2021; 90(2):203-216.
     doi: 10.1002/ana.26146. PMID: 34180076
     Impact factor: 11.274

114. Lainez JM, Ashina M, Belvis R, Diaz-Insa S, Ezpeleta D, Garcia-Azorin D, Gonzalez-Oria C, Guerrero AL, Guillem A, Holle-Lee D, Huerta-Vullanueva M, Irimia P, Leira R, Pascual J, Porta-Etessam J, Pozo-Rosich P, Rodriguez-Vico JS. Sanchez del Rio M, Santos-Lasaosa S, Silberstein S. 1st Post-European Headache Federation Meeting: a review of the latest developments presented at the 2020 European Headache Federation Congress. Rev Neurol 2021;72(s02):S1-S9
     doi: 10.33588/rn.72s02.2021155.PMID: 34180043
     Impact factor: 1.235

115. Pozo-Rosich P (CA), Gil-Gouveia R, Donnet A, Poole AC, Gendolla A, Afridi S, Sanchez-de-la-Rosa R, Terwindt GM, Tassorelli C. Relevant factors for neurologists to define effectiveness of migraine preventive drugs and take decisions on treatment. My-LIFE European Delphi survey. Eur J Pain 2021;25(10):2177-2189
     doi: 10.1002/ejp.1831. Epub 2021 Jul 13.PMID: 34173301
     Impact factor: 3.651

116. Eigenbrodt AK, Ashina H, Khan S, Diener HC, Mitsikostas DD, Sinclair AJ, Pozo-Rosich P, Martelletti P, Ducros A, Lanteri-Minet M, Braschinsky M, Sanchez del Rio M, Oved D, Özge A, Mammadbayli A, Arons M, Skorobogatykh, Romanenko V, Terwindt GM, Pamemeleire K, Sacco S, Reuter U, Lampl C, Schytz HW, Katsarava Z, Steiner TJ, Ashina M. Diagnosis and management of migraine in ten steps. Nat Rev Neurology 2021; 17(8):501-514.
     doi: 10.1038/s41582-021-00509-5. PMID: 34145431
     Impact factor: 44.711

117. Mohamad Safiai NI, Mohamad NA, Basri H, Inche Mat LN, Hoo FK, Abdul Rashid AM, Yusof Khan AHK, Loh WC, Baharin J, Fernandez A, Samsudin IN, Mohamed MH, Siew MC, Lee KW, Ramachandran V, Pozo-Rosich P, Wan Sulaiman WA. High-frequency repetitive magnetic stimulation at dorsolateral prefrontal cortex for migraine prevention: a protocol for a systematic review of controlled trials. PLoS One 2021;16:e0251528
     doi: 10.1371/journal.pone.0251528. eCollection 2021.PMID: 34138860
     Impact factor: 3.752

118. Gago-Veiga AB, Huhn JI, Latysheva N, Vieira Campos A, Torres-Ferrus M, Alpuente A, Sacco S, Frattale I, Ornello R, Ruscheweyh R, Marques IB, Gryglas-Dworak A, Stark C, Gallardo VJ, Pozo-Rosich P. InterMIG: international differences in the therapeutic approach to migraine patients in specialized headache centers. Journal Headache Pain 2021;22:43
     doi: 10.1186/s10194-021-01258-y. PMID: 34030634
     Impact factor: 8.588

119. Sacco S, Lampl C, Maassen van den Brink A, Caponnetto V, Braschinsky M, Ducros A, Little P, Pozo-Rosich P, Reuter U, Sanchez del Rio M, Sinclair AJ, Martelletti P, Katsarava Z, Burden and Attitude to Resistant and Refractory (BARR) Study Group. Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance. Journal Headache Pain 2021, 22(1):39.
     doi: 10.1186/s10194-021-01252-4. PMID: 34006218
     Impact factor: 8.588

120. Tassorelli C, Diener HC, Silberstein SD, Dodick DW, Goadsby PJ, Jensen RH, Magis D, Pozo-Rosich P, Yuan H, Martinelli D, Hoek TVD, Deen M, Ashina M, Terwindt GM. Guidelines of the International Headache Society for clinical trials with neuromodulation devices for treatment of migraine. Cephalalgia 2021;41:1135-1151.
     doi: 10.1177/03331024211010413. PMID: 33990161
     Impact factor: 6.075

121. Pazdera L, Cohen JM, Ning X, Campos VR, Yang R, Pozo-Rosich P. Fremanezumab for the preventive treatment of migraine: subgroup analysis by number of prior preventive treatments with inadequate response. Cephalalgia 2021 41(10):1075-1088.
     doi: 10.1177/03331024211008401. PMID: 33990144
     Impact factor: 6.075

122. Irimia P, Garrido-Cumbrera M, Santos-Lasaosa S, Aguirre-Vazquez M, Correa-Fernandez J, Colomina I, Pozo-Rosich P. Impact of monthly headache days on anxiety, depression and disability in migraine patients: results from the Spanish Atlas. Sci Rep 2021;11:8286
     doi: 10.1038/s41598-021-87352-2. PMID: 33859216
     Impact factor: 4.997

123. Caronna E, Gallardo VJ, Alpuente A, Torres-Ferrus M, Sanchez-Mateo NM, Viguera-Romero J, Lopez-Veloso AC, Lopez-Bravo A, Gago-Veiga AB, Irimia P, Porta-Etessam J, Santos-Lasaosa S, Pozo-Rosich P (CA), Spanish CGRP-COVID Study Group. Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: Present and future implications Neurologia 2021:36:611-7.
     doi: 10.1016/j.nrl.2021.03.003. PMID: 33832802
     Impact factor: 5.486

124. Ornello R, Ahmed F, Negro A, Miscio AM, Santoro A, Alpuente A, Russo A, Silvestro M, Cevoli S, Brunelli N, Vernieri F, Grazzi L, Baraldi C, Guerzoni S, Andreou AP, lambru G, Frattale I, Kamm K, Ruscheweyh R, Russo M, Torelli P, Filatova E, Latysheva N, Gryglas-Dworak A, Straburzynski M, Butera C, Colombo B, Filippi M, Pozo-Rosich P, Martelletti P, Sacco S. Early management of onabotulinumotoxinA treatment in chronic migraine: insights from a real-life European multicenter study. Pain Ther 2021;10:637-650
     doi: 10.1007/s40122-021-00253-0. Epub 2021 Mar 28.PMID: 33778933
     Impact factor: 3.960

125. Ashina M, Katsarava Z, Do TP, Buse DC, Pozo-Rosich P, Özge A, Krymchantowski AV, Lebedeva ER, Ravishankar K, Yu S, Sacco S, Ashina S, Younis A, Steiner TJ, Lipton RB. Migraine: epidemiology and systems of care. Lancet 2021;397(10283):1485-1495.
     doi: 10.1016/S0140-6736(20)32160-7. PMID: 33773613
     Impact factor: 202.731

126. Ashina M, Buse DC, Ashina H, Pozo-Rosich P, Peres MFP, Lee MJ, Terwindt GM, Halker Singh R, Tassorelli C, Do TP, Mitsikostas DD, Dodick DW. Migraine: integrated approaches to clinical management and emerging treatments. Lancet 2021;397(10283):1505-1518.
     doi: 10.1016/S0140-6736(20)32342-4. PMID: 33773612
     Impact factor: 202.731

127. Torres-Ferrus M, Gallardo VJ, Alpuente A, Caronna E, Gine-Cipres E, Pozo-Rosich P (CA). The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study. J Neurol 2021;268:3789-3798
     doi: 10.1007/s00415-021-10523-8. PMID: 33772636
     Impact factor: 6.682

128. Ashina S, Mitsikostas DD, Lee MJ, Yamani N, Wang SJ, Messina R, Ashina H, Buse DC, Pozo-Rosich P, Jensen RH, Diener HC, Lipton RB. Tension-type headache. Nat Rev Dis Primers 2021;7:24
     doi: 10.1038/s41572-021-00257-2. PMID: 33767185
     Impact factor: 65.038

129. Torres-Ferrus M, Lopez-Veloso AC, Gonzalez-Quintanilla V, Gonzalez-García N, Diaz de Teran J, Gago-Veiga A, Camiña J, Ruiz M, Mas-Sala N, Bohorquez S, Gallardo VJ, Pozo-Rosich P. The MIGREX study: prevalence and risk factors of sexual dysfunction among migraine patients. Neurologia 2021;S0213-4853.
     doi: 10.1016/j.nrl.2021.02.006. PMID: 33766414
     Impact factor: 5.486

130. Alpuente A, Gallardo VJ, Caronna E, Torres-Ferrus M, Pozo-Rosich P (CA). Partial and non responders to onabotulinumtoxinA can benefit from anti-CGRP monoclonal preventive treatment: a real-world evidence study. Eur J Neurol 2021;28(7):2378-2382.
     doi: 10.1111/ene.14828. PMID: 33730441
     Impact factor: 6.288

131. Caronna E, Pozo-Rosich P (CA). Headache during COVID-19: lessons for all, implications for the International Classification of Headache Disorders. Headache 2021;61:385-386
     doi: 10.1111/head.14059. PMID: 33522600
     Impact factor: 5.311

132. Diener HC, Ashina M, Durand-Zaleski I, Kurth T, Lanteri-Minet M, Lipton RB, Ollendorf DA, Pozo-Rosich P, Tassorelli C, Terwindt G. Health technology assessment for the acute and preventive treatment of migraine: a position statement of the International Headache Society. Cephalalgia 2021;28(7):2378-2382.
     doi: 10.1111/ene.14828. PMID: 33730441
     Impact factor: 6.075

133. Vilà-Balló A, Martí-Marca A, Torres-Ferrus M, Alpuente A, Gallardo VJ, Pozo-Rosich P. Neurophysiological correlates of abnormal auditory processing in episodic migraine during the interictal period. Cephalalgia 2021;41:45-57
     doi: 10.1177/0333102420951509. PMID: 32838536
     Impact factor: 6.075

134. Belvis R, Irimia P, Seijo-Fernandez F, Paz J, Garcia-March G, Santos-Lasaosa S, Latorre G, Gonzalez-Oria C, Rodríguez R, Pozo-Rosich P, Lainez JM. Neuromodulation in headache and craniofacial neuralgia: guidelines from the Spanish Society of Neurology and the Spanish Society of Neurosurgery. Neurologia 2021;36:61-79
     doi: 10.1016/j.nrl.2020.04.022. PMID: 32718873
     Impact factor: 5.486

135. Pozo-Rosich P, Samman KH, Nicholson RA, Rettiganti M, Pearlman EM, Schwedt TJ. Galcanezumab provides consistent efficacy throughout the dosing interval among patients with episodic and chronic migraine: a post hoc analysis. Adv Therapy 2021;38:3154-3165
     doi: 10.1007/s12325-021-01708-8. PMID: 33950375
     Impact factor: 4.070

136. Pozo-Rosich P (CA), Coppola G, Pascual J, Schwedt TJ. How does the brain change in chronic migraine? Developing disease biomarkers. Cephalalgia 2020;41(5):613-630.
     doi: 10.1177/0333102420974359. Epub 2020 Dec 8. PMID: 33291995
     Impact factor: 6.075

137. Caronna E, Ballve A, Llaurado A, Gallardo VJ, Ariton DM, Lallana S, Lopez Maza S, Olive Gadea M, Quibus L, Restrepo JL, Rodrigo-Gisbert M, Vilaseca A, Hernandez Gonzalez M, Martinez Gallo M, Alpuente A, Torres-Ferrus M, Pujol Borrell R, Alvarez-Sabin J, Pozo-Rosich P (CA). Headache: a striking prodromal and persistent symptom, predictive of COVID-19 clinical evolution. Cephalalgia 2020;40:1410-1421
     doi: 10.1177/0333102420965157. PMID: 33146036
     Impact factor: 6.295

138. Pascual J, Pozo-Rosich P, Carrillo I, Rodriguez-Justo S, Jimenez-Hernandez D, Layos-Romero A, Bailon-Santamaría C, Torres A, Martinez-Garcia A, Ignacio E, Mira JJ. Proposal of a clinical care pathway for quality and safe management of headache patients: a consensus study report. BMJ Open 2020;10:e037190
     doi: 10.1136/bmjopen-2020-037190. PMID: 33127628
     Impact factor: 2.692

139. Mulleners WM, Kim BK, Lainez MJA, Lanteri-Minet M, Pozo-Rosich P, Wang S, Tockhorn-Heidenreich MS, Aurora SK, Nichols RM, Yunes-Medina L, Detke HC. Safety and efficacy of galcanezumab in patients whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicenter, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol 2020;19:814-825
     doi: 10.1016/S1474-4422(20)30279-9. PMID: 32949542
     Impact factor: 44.182

140. Gonzalez-Oria C, Belvis R, Cuadrado ML, Diaz-Insa S, Guerrero-Peral AL, Huerta M, Irimia P, Lainez JM, Latorre G, Leira R, Oterino A, Pascual J, Porta-Etessam J, Pozo-Rosich P, Sanchez del Rio M, Santos-Lasaosa S. Document of revision and updating of medication overuse headache (MOH). Neurologia 2021;36:229-240.
     doi: 10.1016/j.nrl.2020.04.029. PMID: 32917437
     Impact factor: 5.486

141. Pozo-Rosich P (CA), Martin-Delgado J, Layos-Romero A, Pascual J, Bailon C, Guerrero-Peral AL, Ignacio E, Torres A, Mira JJ. Specialised headache units, a feasible alternative in Spain. Rev Neurol 2020;71:199-204
     doi: 10.33588/rn.7106.2020269. PMID: 32895902
     Impact factor: 0.870

142. Ruscheweyh R, Athwal B, Gryglas-Dworak A, Frattale I, Latysheva N, Ornello R, Pozo-Rosich P, Sacco S, Torres-Ferrus M, Stark CD. Wear-Off of OnabotulinumtoxinA effect over the treatment interval in chronic migraine: a retrospective chart review with analysis of headache diaries. Headache 2020;60:1673-1682
     doi: 10.1111/head.13925. Epub 2020 Aug 14. PMID: 32797631
     Impact factor: 5.887

143. Diener HC, Tassorelli C, Dodick DW, Silberstein SD, Lipton RB, Ashina M, Becker WJ, Ferrari MD, Goadsby PJ, Pozo-Rosich P, Wang SJ, Houle TT, Hoek TCVD, Martinelli D, Terwindt GM; International Headache Society Clinical Trials Committee. Guidelines of the International Headache Society for Controlled Trials of Preventive Treatment of Migraine Attacks in Episodic Migraine in Adults. Cephalalgia 2020;40:1026-1044
     doi: 10.1177/0333102420941839. Epub 2020 Jul 28.PMID: 32722936
     Impact factor: 6.295

144. Fonseca E, Torres-Ferrus M, Gallardo VJ, Macaya A, Pozo-Rosich P (CA). Impact of puberty in pediatric migraine: a pilot prospective study. J Clin Neurol 2020;16(3):416-422
     doi: 10.3988/jcn.2020.16.3.416.PMID: 32657062
     Impact factor: 3.077

145. Torres-Ferrus M, Gallardo VJ, Alpuente A, Pozo-Rosich P (CA). Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA. J Headache Pain 2020;21(1):88
     doi: 10.1186/s10194-020-01157-8.PMID: 32652924

146. Irimia P, Garrido-Cumbrera M, Santos-Lasaosa S, Braçe O, Colomina I, Blanch C, Pozo-Rosich P (CA). Estimating the savings of a migraine free life: results from the Spanish Atlas. Eur J Neurol 2020;27(12):2616-2624.
     doi: 10.1111/ene.14431. Epub 2020 Aug 8. PMID: 32643853
     Impact factor: 6.089

147. Sacco S, Braschinsky M, Ducros A, Lampl C, Little P, van den Brink AM, Pozo-Rosich P, Reuter U, de la Torre ER, Del Rio MS, Sinclair AL, Katsarava Z, Martelletti P. European Headache Federation consensus on the definition of resistant and refractory migraine: developed with the endorsement of the European Migraine & Headache Alliance (EMHA). J Headache Pain 2020;21:76
     doi: 10.1186/s10194-020-01130-5.PMID: 32546227
     Impact factor: 7.277

148. Pozo-Rosich P (CA), Layos-Romero A, Martin-Delgado J, Pascual J, Bailon C, Tentor A, Santiago A, Ignacio E, Torres A, Mira JJ. Low-value care practice in headache: a Spanish mixed methods research study. J Headache Pain 2020;21:74
     doi: 10.1186/s10194-020-01147-w. PMID: 32522142
     Impact factor: 7.277

149. Gonzalez-García N, Pozo-Rosich P. Comments on “Headache: Pregnancy and breastfeeding. Recommendations of the Spanish Society of Neurology’s Headache Study Group. Neurologia 2020;36(2):176.
     doi: 10.1016/j.nrl.2020.01.005. Epub 2020 May 20.PMID: 32444176
     Impact factor: 5.486

150. Alpuente A, Gallardo VJ, Torres-Ferrus M, Santos-Lasaosa S, Guerrero A, Lainez JM, Viguera J, Gago-Veiga A, Irimia P, Del Rio MS, Pozo-Rosich P (CA). Evaluation of the concomitant use of oral preventive treatments and OnabotulinumtoxinA in chronic migraine: the PREVENBOX study. Eur J Neurol 2020;27:2102-2108
     doi: 10.1111/ene.14331. PMID: 32421912
     Impact factor: 6.089

151. Bryois J, Skene NG, Folkmann Hansen T, Kogelman JA, Watson HJ, Liu Z, et al. Genetic identification of cell types underlying brain complex traits yields insights into the etiology of Parkinson’s Disease. Nat Genet 2020; 52(5):482-493.
     doi: 10.1038/s41588-020-0610-9. PMID: 32341526
     Impact factor: 38.330

152. Siewert KM, Klarin D, Damrauer SM, Chang KM, Taso PS, Assimes TL, Davey Smith G, Voight BF, the International Headache Genetics Consortium. Cross-trait analysis with migraine reveal widespread pleiotropy and suggest a vascular component to migraine headache. Int J Epidemiol 2020;49:1022-1031
     doi: 10.1093/ije/dyaa050. PMID: 32306029
     Impact factor: 7.196

153. Alpuente A, Tassorelli C, Diener HC, Silberstein SD, Pozo-Rosich P (CA). Have the IHS Guidelines for controlled trials of acute treatment of migraine attacks been followed? Laying the ground for the 4^th Cephalalgia 2020;40(8):778-787.
     doi: 10.1177/0333102420906843. PMID: 32056459
     Impact factor: 6.295

154. Alpuente A, Gallardo VJ, Torres-Ferrus M, Alvarez-Sabin J, Pozo-Rosich P (CA). Short and mid-term predictors of response to onabotulinumtoxinA: real-life experience observational study. Headache 2020;60(4):677-685
     doi: 10.1111/head.13765. PMID: 32086801
     Impact factor: 5.887

155. Caronna E, Gallardo VJ, Fonseca E, Gomez-Galvan JB, Alpuente A, Torres-Ferrus M, Pozo-Rosich P (CA). How does migraine change after 10 years? A clinical cohort follow-up analysis. Headache 2020;60:916-928
     doi: 10.1111/head.13774. PMID: 32068897
     Impact factor: 5.887

156. Kudrow D, Krege JH, Hundemer HP, Berg PH, Khanna R, Ossipov MH, Pozo-Rosich P. Issues impacting adverse event frequency and severity: differences between randomized phase 2 and phase 3 clinical trials for lasmiditan. Headache 2020;60:576-588
     doi: 10.1111/head.13731. PMID: 31943195
     Impact factor: 5.887

157. Pozo-Rosich P (CA), Torres-Ferrus M. When does chronic migraine strike? Cephalalgia 2020;40:411-12
     doi: 10.1177/0333102419885375. PMID: 31757168
     Impact factor: 4.868

158. Charles A, Pozo-Rosich P. Targeting calcitonin gene-related peptide: a new era in migraine therapy. Lancet 2019;394:1765-1774.
     doi: 10.1016/S0140-6736(19)32504-8. PMID: 31668411
     Impact factor: 60.390

159. Diener HC, Goadsby PJ, Ashina M, Al-Karagholi MA, Sinclair A, Mitsikostas D, Magis D, Pozo-Rosich P, Sieira PI, Lainez MJ, Gaul C, Silver N, Hoffmann J, Marin J, Liebler E, Ferrari MD; PREMIUM Study Group. Non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine: the multicenter, double-blind, randomised, sham-controlled PREMIUM trial. Cephalalgia 2019;39:1475-1487
     doi: 10.1177/0333102419876920. PMID: 31522546
     Impact factor: 4.868

160. Santos-Lasaosa S, Belvis R, Cuadrado ML, Diaz-Insa S, Gago-Veiga A, Guerrero-Peral AL, Huerta M, Irimia P, Lainez JM, Latorre G, Leira R, Pascual J, Porta-Etessam J, Sanchez del Rio M, Viguera J, Pozo-Rosich P. Calcitonin gene-related peptide in migraine: from pathophysiology to treatment. Neurologia 2022;37(5):390-402.
     doi: 10.1016/j.nrl.2019.03.013. Epub 2019 Jul 17. PMID: 31326215
     Impact factor: 2.283

161. Pozo-Rosich P, Martinez-García A, Pascual J, Ignacio E, Guerrero-Peral AL, Balseiro-Gomez J, Porta-Etessam J, Latorre-Gonzalez G, Layos-Romero A, Lucas C, Mira JJ. Quality assurance in specialized headache units in Spain: an observational prospective study. Journal Headache Pain 2019;20(1):73
     doi: 10.1186/s10194-019-1020-1.PMID: 31238877
     Impact factor: 4.797

162. Alpuente A, Gallardo VJ, Torres-Ferrus M, Alvarez-Sabin J, Pozo-Rosich P (CA). Early efficacy and late gain in chronic and high frequency episodic migraine with onabotulinumtoxinA. Eur J Neurol 2019, 26:1464-1470
     doi: 10.1111/ene.14028. PMID: 31220392
     Impact factor: 4.516

163. Gonzalez-Garcia N, Diaz de Teran J, Lopez-Veloso AC, Mas-Sala N, Minguez-Olaondo A, Ruiz-Piñero M, Gago-Veiga AB, Santos-Lasaosa S, Viguera-Romero J, Pozo-Rosich P. Headache: pregnancy and breastfeeding. Recommendations of the Spanish Society of Neurology’s Headache Study Group. Neurologia 2021. S2173-5808(21)00138-3
     doi: 10.1016/j.nrl.2018.12.003. PMID: 31047730
     Impact factor: 3.900

164. Leira Y, Pozo-Rosich P, Torres-Ferrus M, Orlandi M, Lainez JM, Alvaro LC, Monzon MJ, Guerrero A, Garcia-Azorin D, Belvis R, Gonzalez-Oria C, Gago-Veiga AB, Latorre G, Santos S, Cuadrado ML, Blanco J, Leira R, D’Aiuto F. Self-reported periodontitis and migraine: results from a multi-center, cross-sectional survey in Spain. Odontology 2019; 107:530-535
     doi: 10.1007/s10266-019-00430-w. PMID: 31030294
     Impact factor: 1.840

165. Abu-Arafeh I, Pozo-Rosich P. Board Walk – April 2019. Cephalalgia 2019;39:569-570
     doi: 10.1177/0333102419834487.PMID: 30974968

166. Torres-Ferrus M, Alpuente A, Pozo-Rosich P (CA). How much do calcitonin gene-related peptide monoclonal antibodies improve the quality of life in migraine? A patient’s perspective. Curr Opin Neurol 2019;32:395-404
     doi: 10.1097/WCO.0000000000000689. PMID: 30950844
     Impact factor: 4.207

167. Bohorquez S, Pozo-Rosich P. Protocol for diagnosis and treatment of recent onset headache. Medicine 2019
168. Gago-Veiga AB, Camiña Muñiz J, García-Azorín D, González-Quintanilla V, Ordás CM, Torres-Ferrus M, Santos-Lasaosa S, Viguera-Romero J, Pozo-Rosich P. Headache: What to ask, how to examine and which scales to use. Recommendations of the Spanish Society of Neurology’s Headache Study Group. Neurologia 2022 Sep;37(7):564-574.
     doi: 10.1016/j.nrl.2018.12.006. PMID: 30929913
     Impact factor: 2.283

169. Reuter U, McClure C, Liebler E, Pozo-Rosich P. Non-invasive neuromodulation for migraine and cluster headache: a systematic review of clinical trials. J Neurol Neurosurg Psychiatry 2019; 2019;90(7):796-804
     doi: 10.1136/jnnp-2018-320113. PMID: 30824632
     Impact factor: 8.263

170. Diener HC, Tassorelli C, Dodick DW, Silberstein SD, Lipton RB, Ashina M, Becker WJ, Ferrari MD, Goadsby PJ, Pozo-Rosich P, Wang SJ, Mandrekar J; International Headache Society Clinical Trials Standing Committee. Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition. Cephalalgia 2019 May;39(6):687-710
     doi: 10.1177/0333102419828967. PMID: 30806518
     Impact factor: 4.868

171. Carrillo I, Pozo-Rosich P, Guilabert M, Ignacio E, Pascual J, Porta-Etessam J, Guerrero-Peral AL, Mira JJ. Portfolio of services and basic table of quality indicators for Headache Units: a consensus study. Rev Neurol 2019;68:118-22.
     PMID: 30687919
     Impact factor: 0.652

172. Caronna E, Gallardo VJ, Hernandez-Beltran N, Torres-Ferrus M, Pozo-Rosich P (CA). OnabotulinumtoxinA: an effective tool in the therapeutic arsenal for chronic migraine with medication overuse. Frontiers Neurology 2018;9:808
     doi: 10.3389/fneur.2018.00808. PMID: 30386285
     Impact factor: 2.635

173. Bendtsen L, Sacco S, Ashina M, Mitsikostas M, Ahmed F, Pozo-Rosich P, Martelletti P. Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation. J Headache Pain 2018;19:91
     doi: 10.1186/s10194-018-0921-8. PMID: 30259200
     Impact factor: 3.918

174. Brainstorm Consortium. Analysis of shared heritability in common disorders of the brain. Science 2018;360(6395)
     doi: 10.1126/science.aap8757. PMID: 29930110
     Impact factor: 41.063

175. Torres-Ferrus M, Vila-Sala M, Quintana M, Ajanovic S, Gallardo VJ, Gomez JB, Alvarez-Sabin J, Macaya A, Pozo-Rosich P (CA). Headache, comorbidities and lifestyle in an adolescent population (The TEENs Study). Cephalalgia 2019;39:91-99
     doi: 10.1177/0333102418777509. PMID: 29771141
     Impact factor: 4.868

176. Yang Y, Zhao H, Boomsma DI, Ligthart L, Belin AC, Smith GD, Esko T, Freilinger TM, Hansen TF, Ikram MA, Kallela M, Kubisch C, Paraskevi C, Strachan DP, Wessman M; International Headache Genetics Consortium, van den Maagdenberg AMJM, Terwindt GM, Nyholt DR. Molecular genetic overlap between migraine and major depressive disorder. Eur J Hum Genet 2018;26:1202-1216
     doi: 10.1038/s41431-018. PMID: 29995844
     Impact factor: 3.650

177. Gormley P, Kurki MI, Hiekkala ME, et al. Common variant burden contributes to the familial aggregation of migraine in 1589 families. Neuron 2018;98(4):743-753
     doi: 10.1016/j.neuron.2018.04.014. PMID: 29731251
     Impact factor: 14.403

178. Dominguez C, Pozo-Rosich P, Leira Y, Leira R. Unilateral pain and shorter duration of chronic migraine are significant predictors of response to onabotulinumtoxinA. Eur J Neurol 2018;25:e48.
     doi: 10.1111/ene.13570.PMID: 29575364

179. Tassorelli C, Diener HC, Dodick DW, Silberstein SD, Lipton RB, Ashina M, Becker WJ, Ferrari MD, Goadsby PJ, Pozo-Rosich P, Wang SJ; International Headache Society Clinical Trials Standing Committee. Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia 2018;38:815-832
     doi: 10.1177/0333102418758283. PMID: 29504482

Impact factor: 4.438

180. May A, Schwedt TJ, Magis D, Pozo-Rosich P, Evers S, Wang SJ. Cluster headache. Nat Rev Dis Primers 2018; 1;4:18006
     doi: 10.1038/nrdp.2018.6.PMID: 29493566
     Impact factor: 32.274

181. Dominguez C, Pozo-Rosich P, Torres-Ferrus M, Hernandez-Beltran N. Jurado-Cobo C, Gonzalez-Oria C, Santos S, Monzon MJ, Latorre G, Alvaro LC, Gago A, Gallego A, Medrano V, Huerta M, Garcia-Alhama J, Belvis R, Leira Y, Leira R. OnabotulinumtoxinA in chronic migraine: predictors of response. A prospective multicentre descriptive study. Eur J Neurol 2018;25:411-416
     doi: 10.1111/ene.13523. PMID: 29171146
     Impact factor: 4.387

182. Santos Lasaosa ML, Cuadrado ML, Gago-Veiga AB, Guerrero Peral AL, Irimia P, Lainez JM, Leira R, Pascual J, Porta-Etessam J, Sanchez del Rio M, Viguera J, Pozo-Rosich P. Evidence and experience with the use of onabotulinumtoxinA in trigeminal neuralgia and primary headaches other than chronic migraine. Neurologia 2017; pii: S0213-4853(17)30319-5
     doi: 10.1016/j.nrl.2017.09.003. PMID: 29169811
     Impact factor: 2.283

183. Gago-Veiga AB, Santos-Lasaosa S, Cuadrado ML, Guerrero AL, Irimia P, Lainez JM, Leira R, Pascual J, Sanchez del Rio M, Viguera J, Pozo-Rosich P. Evidence and experience with onabotulinumtoxinA in chronic migraine. Recommendations for daily clinical practice. Neurologia 2019 Jul-Aug;34(6):408-417.
     doi: 10.1016/j.nrl.2017.09.008. PMID: 29169810
     Impact factor: 2.283

184. Gago-Veiga AB, García-Azorín D, Mas-Sala N, Ordás CM, Ruiz-Piñero M, Torres-Ferrus M, Santos Lasaosa S, Viguera Romero J, Pozo-Rosich P. How and when to refer patients diagnosed with primary headache and craniofacial neuralgia in the emergency department or primary care: recommendations of the Spanish Society of Neurology’s Study Group. Neurologia 2020 Apr;35(3):176-184.
     doi: 10.1016/j.nrl.2017.08.001. PMID: 28870393
     Impact factor: 3.109

185. Gago-Veiga AB, Diaz de Terán J, Gonzalez-García N, Gonzalez-Oria C, Gonzalez-Quintanilla V, Minguez-Olaondo A, Santos-Lasaosa S, Viguera Romero J, Pozo-Rosich P. How and when to refer patients diagnosed with secondary headache and other craniofacial pain in the emergency department and primary care: recommendations of the Spanish Society of Neurology’s Headache Study Group. Neurologia 2020 Apr;35(3):176-184.
     doi: 10.1016/j.nrl.2017.08.001. PMID: 28870393
     Impact factor: 3.109

186. Winsvold BS, Bettella F, Witoelar A, Anttila V, Gormley P, Kurth T, Terwindt GM, Freilinger TM, Frei O, Shadrin A, Wang Y, Dale AM, van den Maagdenberg AMJM, Chasman DI, Nyholt DR, Palotie A, Andreassen Matharu M, Halker R, Pozo-Rosich P, DeGryse R, Manack Adams A, Aurora SK. The impact of onabotulinumtoxinA on severe headache days: PREEMPT 56-week pooled analysis. J Headache Pain 2017;18:78.
     doi: 10.1186/s10194-017-0784-4. PMID: 28766236
     Impact factor: 3.403

187. Ramos ML, García-Cabo C, Leira R, Domínguez C, Pozo-Rosich P, Vila C, Laínez MJ, Pascual J. Comorbidity between idiopathic overactive bladder and chronic migraine. Cephalalgia 2018 Mar;38(3):581-584.
     doi: 10.1177/0333102417690127. PMID: 28114808
     Impact factor: 4.438

188. Winsvold BS, Bettella F, Witoelar A, Anttila V, Gormley P, Kurth T, Terwindt GM, Freilinger TM, Frei O, Shadrin A, Wang Y, Dale AM, van den Maagdenberg AMJM, Chasman DI, Nyholt DR, Palotie A, Andreassen OA, Zwart JA; International Headache Genetics Consortium. Shared genetic risk between migraine and coronary artery disease: A genome-wide analysis of common variants. PLoS One 2017;12:e0185663
     doi: 10.137/journal.pone.0185663. PMID 28957430
     Impact factor: 2.766

189. Sintas C, Fernandez-Castillo N, Vila-Pueyo M, Pozo-Rosich P, Macaya A, Cormand B. Transcriptomic changes in rat cortex and brainstem after cortical spreading depression with or without pre-treatment with migraine prophylactic drugs. J Pain 2017;18(4):366-375.
     doi: 10.1016/j.jpain.2016.11.007. PMID: 27919769
     Impact factor: 4.859

190. Aurora S, Halker R, Pozo-Rosich P, DeGryse R, Manack Adams A, Matharu M, Poster 411 The Impact of OnabotulinumtoxinA on Severe Headache Days: PREEMPT 24-Week pooled analysis. PM R 2016;8(9S):S296
     doi: 10.1016/j.pmrj.2016.07.338. PMID: 27673163
     Impact factor: 1.785

191. Santos Lasaosa S, Gago Veiga A, Guerrero Peral AL, Viguera Romero J, Pozo-Rosich P. Patterns of anaesthetic pericranial nerve block in headache patients. Neurologia 2018 Apr;33(3):160-164.
     doi: 10.1016/j.nrl.2016.05.016. PMID: 27461182
     Impact factor: 2.038

192. Santos Lasaosa S, Cuadrado Perez ML, Guerrero Peral AL, Huerta Villanueva M, Porta-Etessam J, Pozo-Rosich P, Pareja JA. Guía consenso sobre técnicas de infiltración anestésica de nervios pericraneales. Neurologia 2017 Jun;32(5):316-330.
     doi: 10.1016/j.nrl.2016.04.017. PMID: 27342391
     Impact factor: 1.938

193. Gormley P, Anttila V, Winsvold BS, Palta P, Esko T, Pers TH, et al. Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for migraine. Nat Genet 2016;48:856-66.
     doi: 10.1038/ng.3598. PMID: 27322543
     Impact factor: 27.959

194. Gago-Veiga AB, Santos-Lasaosa S, Viguera J. Pozo-Rosich P (CA). ¿Se interesan los residentes de neurología en cefaleas? Neurologia 2018 Jan-Feb;33(1):1-7.
     doi: 10.1016/j.nrl.2016.04.013. PMID: 27328892
     Impact factor: 2.038

195. Torres-Ferrús M, Quintana M, Fernandez-Morales J, Alvarez-Sabin J, Pozo Rosich P (CA). When does chronic migraine strike? A clinical comparison according to the headache days suffered per month. Cephalalgia 2017;37:104-113
     doi: 10.1177/0333102416636055. PMID: 26961321
     Impact factor: 3.886

196. Winsvold BS, Nelson CP, Malik R, Gormley P, Anttila V, Vander Heiden J, Elliott KS, Jacobsen LM, Palta P, Amin N, de Vries B, Hämäläinen E, Freilinger T, Ikram MA, Kessler T, Koiranen M, Ligthart L, McMahon G, Pedersen LM, Willenborg C, Won HH, Olesen J, Artto V, Assimes TL, Blankenberg S, Boomsma DI, Cherkas L, Davey Smith G, Epstein SE, Erdmann J, Ferrari MD, Göbel H, Hall AS, Jarvelin MR, Kallela M, Kaprio J, Kathiresan S, Lehtimäki T, McPherson R, März W, Nyholt DR, O’Donnell CJ, Quaye L, Rader DJ, Raitakari O, Roberts R, Schunkert H, Schürks M, Stewart AF, Terwindt GM, Thorsteinsdottir U, van den Maagdenberg AM, van Duijn C, Wessman M, KurthT, Kubisch C, Dichgans M, Chasman DI, Cotsapas C, Zwart JA, Samani NJ, Palotie A; CARDIoGRAM Consortium and the International Headache Genetics Consortium. Genetic analysis for a shared biological basis between migraine and coronary artery disease. Neurol Genet 2015 2;1:e10.
     doi: 10.1212/NXG.0000000000000010
     Impact factor: 3.509

197. Zhao H, Eising E, de Vries B, Vijfhuizen LS; International Headache Genetics Consortium, Anttila V, Winsvold BS, KurthT, Stefansson H, Kallela M, Malik R, Stam AH, Ikram MA, Ligthart L, Freilinger T, Alexander M, Müller-Myhsok B, Schreiber S, Meitinger T, Aromas A, Eriksson JG, Boomsma DI, van Duijn CM, Zwart JA, Quaye L, Kubisch C, Dichgans M, Wessman M, Stefansson K, Chasman DI, Palotie A, Martin NG, Montgomery GW, Ferrari MD, Terwindt GM, van den Maagdenberg AM, Nyholt DR. Gene-based pleiotropy across migraine with aura and migraine without aura patient groups. Cephalalgia 2016;36:648-57
     Impact factor: 3.609

198. Torres-Ferrús M, Pozo-Rosich P (CA). Posicionamiento de las unidades de cefalea en el ámbito de la neurología: la importancia de la toxina botulínica y otras terapias en el tratamiento de la cefalea. Rev Neurol 2015;61(Suppl 1:S3-7)
     PMID: 26337644
     Impact factor: 1.79

199. Pozo-Rosich P (CA). Unidades de cefalea en el ámbito de la neurología. Rev Neurol 2015;61(Suppl 1):S1-2.
     PMID: 26337641
     Impact factor: 1.79

200. Pozo-Rosich P (CA), Storer RJ, Charbit A, Goadsby PJ. Periaqueductal gray calcitonin gene-related peptide modulates trigeminovascular neurons. Cephalalgia 2015,35(14):1298-307.
     doi: 10.1177/0333102415576723. PMID: 25792688
     Impact factor: 6.052

201. Sintas C, Fernandez-Morales J, Vila-Pueyo M, Narberhaus B, Arenas C, Pozo-Rosich P, Macaya A, Cormand B. Replication study of previous migraine genome-wide association study findings in a Spanish sample of migraine with aura. Cephalalgia 2015;35(9):776-82.
     doi: 10.1177/033310241455784. PMID: 25388962
     Impact factor: 6.052

202. Nyholt DR; International Headache Genetics Consortium, Anttila V, Winsvold BS, KurthT, Stefansson H, Kallela M, Malik R, Vries Bd, Terwindt GM, Ikram MA, Stam AH, Ligthart L, Freilinger T, Alexander M, Muller-Myhsok B, Schreiber S, Meitinger T, Aromaa A, Eriksson JG, Kaprio J, Boomsma DI, Duijn Cv, Raitakari O, Järvelin MR, Zwart JA, Quaye L, Strachan DP, Kubisch C, Ferrari MD, van den Maagdenberg AM, Dichgans M, Wessman M, Smith GD, Stefansson K, Chasman DI, Palotie A. Concordance of genetic risk across migraine subgroups: impact on current and future genetic association studies. Cephalalgia 2015;35:489-99
203. Chasman DI, Anttila V, Buring JE, Ridker PM, Schürks M, KurthT; International Headache Genetics Consortium. Selectivity in genetic association with sub-classified migraine in women. PLoS Genet 2014;10:e1004366
204. Sanchez del Rio M, Leira R, Pozo-Rosich P, Lainez JM, Alvarez R, Pascual J. Errors in recognition and management are still frequent in patients with cluster headache. European Neurology 2014;72:209-212.
     doi: 10.1159/000362517. PMID: 25227490
     Impact factor (2013) 1.362

205. Louter M, Fernandez-Morales J, de Vries B, Winsvold B, Anttila V, Fernandez-Cadenas I, Vila-Pueyo M, Sintas C, van Duijn C, Cormand B, Alvarez-Sabin J, Montaner J, Ferrari M, van den Maagdenberg A, Palotie A, Zwart J, Macaya A, Terwindt G, Pozo-Rosich P (CA). Candidate-gene association study searching for genetic factors involved in migraine chronification. Cephalalgia 2015;35:500-7.
     doi: 10.1177/0333102414547141. PMID: 25169732
     Impact factor (2013) 4.121. Clinical Neurology 32 out of 194/ Neurosciences 71 out of 251.

206. Gomez-Mancilla B, Brand R, Jürgens TP, Göbel H, Sommer C, Evers S, Sommer M, Campos V, Kalkman HO, Hariry S, Pezous N, Johns D, Diener HC, BGG492 Study Group. Randomized, multicenter trial to assess the efficacy, safety and tolerability of a single dose of a novel AMPA receptor antagonist BGG492 for the treatment of acute migraine attacks. Cephalalgia 2014;34:103-13.
207. Pozo-Rosich P (CA). What benefits does the preventive treatment of migraine have? Rev Neurol 2014;58 Suppl 2:S21-6.
     PMID: 24687881
     Impact factor (2013) 0.926

208. Pozo-Rosich P (CA). Importance of diagnosis and treatment in chronic migraine. Rev Neurol 2014;58. Suppl 2:S1.
     PMID: 24687879
     Impact factor (2013) 0.926.

209. Pozo-Rosich P (CA). Chronic migraine: its epidemiology and impact. Rev Neurol 2012;54. Suppl 2:S3-11.
     PMID: 22532240
     Impact factor (2011) 1,083.

210. Sintas C, Carreño O, Fernandez-Morales J, Cacheiro P, Sobrido MJ, Naberhaus B, Pozo-Rosich P, Macaya A, Cormand B. A replication study of a GWAS finding in migraine does not identify association in a Spanish case-control sample. Cephalalgia 2012;32:1076-80.
     doi: 10.1177/0333102412457090. PMID: 22908361
     Impact factor (2011) 3,430. Ranking: 44/191 (Clinical Neurology), 89/243 (Neurosciences)

211. Freilinger T, Anttila V, de Vries B, Malik R, Kallela M, Terwindt G, Pozo-Rosich P, et al. For the International Headache Genetics Consortium. Genome-wide association analysis identifies several susceptibility loci for migraine without aura. Nature Genetics 2012;44:777-782.
     doi: 10.1038/ng.2307. PMID: 22683712
     Impact factor (2011) 35,532. Ranking 1/156 in genetics.

212. Färkkilä M, Diener HC, Géraud G, Láinez M, Schoenen J, Harner N, Pilgrim A, Reuter U, & COL MIG-202 study group. Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised placeo-controlled, parallel-group, dose-ranging study. Lancet Neurol 2012;11:405-13.
     doi: 10.1016/S1474-4422(12)70047-9. PMID: 22459549
     Impact factor: 23.917

213. Poca MA, Galard R, Serrano E, Merino MA, Pozo-Rosich P, Solana E, Mestres O, de la Calzada MD, Sahuquillo J. Normal hypocretin-1 (orexin A) levels in cerebrospinal fliud in patients with idiopathic intracranial hypertension. Acta Neurochir Suppl. 2012;114:221-5.
     doi: 10.1007/978-3-7091-0956-4_43. PMID: 22327697
     Impact factor 1,329.

214. Carreño O, Corominas R, Fernandez-Morales J, Camiña M, Sobrido MJ, Fernandez-Fernandez JM, Pozo-Rosich P, Cormand B, Macaya A. SNP variants within the vanilloid TRPV1 and TRPV3 receptor genes are associated with migraine in the Spanish population. Am J Med Genet B Neuropsychiatr Genet 2012;159B(1):94-103.
     doi: 10.1002/ajmg.b.32007. PMID: 22162417
     Impact factor (2011): 3,430. Ranking WoS: 42/157 (Genetics & Hereditary), 30/129 (Psychiatry).

215. Pascual J, Sanchez del Río M, Jimenez MD, Lainez-Andres JM, Mateos V, Leira R, Pozo-Rosich P, Guzman-Quilo C. La migraña crónica vista por el neurólogo y el paciente: resultados del proyecto CIEN-mig (III). Rev Neurol 2010;50:705-710.
     PMID: 20533248
     Impact factor 1,234

216. Pascual J, Sanchez del Río M, Jimenez MD, Lainez-Andres JM, Mateos V, Leira R, Pozo-Rosich P, Guzman-Quilo C. Satisfacción del paciente con migraña que acude a consultas de neurología: resultados del proyecto CIEN-mig (II). Rev Neurol 2010;50:641-645.
     PMID: 20514635
     Impact factor 1,234

217. Pascual J, Sanchez del Río M, Jimenez MD, Lainez-Andres JM, Mateos V, Leira R, Pozo-Rosich P, Guzman-Quilo C. Actitud del neurólogo español frente a la migraña: resultados del proyecto CIEN-mig (I). Rev Neurol 2010;50:577-583.
     PMID: 20473832
     Impact factor 1,234

218. Río-Espinola A, Mendióroz M, Domingues-Montanari S, Pozo-Rosich P, Solé E, Fernández-Morales J, Fernández-Cadenas I, Montaner J. CADASIL management or what to do when there is little one can do. Expert Rev Neurother 2009;9:197-210.
     doi: 10.1586/14737175.9.2.197. PMID: 19210195
     Impact factor 2,991.

219. Graus F, Vincent A, Pozo-Rosich P, Sabater L, Saiz A, Dalmau J. Anti-glial nuclear antibody: marker of lung cancer-related paraneoplastic neurological syndromes. J Neuroimmunol 2005; 165:166-71.
     doi: 10.1016/j.jneuroim.2005.03.020. PMID: 15949849
     Impact factor 2,92.

220. Siow C, Pozo-Rosich P, Silberstein SD. Frovatriptan for the treatment of cluster headache. Cephalalgia 2004;24:1045-8.
     doi: 10.1111/j.1468-2982.2004.00734.x. PMID: 15566418
     Impact factor 3,775.

221. Pozo-Rosich P, Clover L, Saiz A, Vincent A, Graus F. Voltage-gated potassium channel antibodies in limbic encephalitis. Ann Neurol 2003;54:530-3.
     doi: 10.1002/ana.10713. PMID: 14520669
     Impact factor 8,813.

222. Villoslada P, Juste C, Tintore M, Llorens V, Codina G, Pozo-Rosich P, Montalban X. The immune response against herpesvirus is more prominent in the early stages of MS. Neurology 2003;60:1944-1948.
     doi: 10.1212/01.wnl.0000069461.53733.f7. PMID: 12821737
     Impact factor 6,014.

223. Young WB, Pozo-Rosich P, Paolone MF. Alternative Therapies for Headache. Curr Treat Options Neurol 2003;5:441-553.
     doi: 10.1007/s11940-996-0013-y. PMID: 14516522
     Impact factor 1,556.
224. Graus F, Lang B, Pozo-Rosich P, Saiz A, Casamitjana R, Vincent A. P/Q type calcium-channel antibodies in paraneoplastic cerebellar degeneration with lung cancer. Neurology. 2002; 59:764-6.
     doi: 10.1212/wnl.59.5.764.PMID: 12221175.
     Impact factor 6,014.

225. Pozo-Rosich P, Villoslada P, Canton A, Simo R, Rovira A, Montalban X. Reversible white matter alterations in encephalopathy associated with autoimmune thyroid disease. J Neurol 2002; 249:1063-5.
     doi: 10.1007/s00415-002-0788-z.PMID: 12195455. Impact factor 2,477.